Union Therapeutics

[On Demand]
Search General Info
Search Education
Search Partnering Companies
UNION Therapeutics is a privately held, clinical-stage, pharmaceutical company dedicated to the development of novel medicines based on compounds demonstrating both microbiological and immunological effects.
UNION is currently developing two late-stage drug candidates:
- Orismilast, a potential best-in-class oral PDE4 inhibitor, originally developed by LEO Pharma. Union is aiming to position Orismilast as an efficacious, safe and convenient oral treatment for multiple inflammatory conditions, ahead of expensive injectable biologics. Union is preparing several Phase 2b trials in different inflammatory indications, including psoriasis and atopic dermatitis.
- Niclosamide, a broad-spectrum anti-viral, which Union is developing as nasal spray and nebulizer for inhalation for the treatment and prevention of respiratory infections, including COVID-19. Niclosamide is currently being evaluated in several potential registrational trials in high-risk as well as infected COVID-19 patients.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Denmark
Year Founded:
2011
Main Therapeutic Focus:
Lead Product in Development:
Orismilast
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chief Business Offcer
UNION therapeutics A/S